Abstract
steroid-induced myopathy, and mood swings with hyperalgesia; these were managed with insulin and pregabalin. • Permission was obtained from the hospital’s Pharmacy & Therapeutics Committee for experimental use of Rituximab (anti-CD20) (written informed consent obtained from patient); started at 560mg IV weekly x 4. • Her symptoms improved dramatically after the 3rd and 4th infusions, with successful tapering of the IV steroid dose, and transfer to oral prednisone with ongoing taper. • Tracheostomy was removed, she was transferred to a rehab facility for inpatient physiotherapy. • She was discharged home 3 weeks later off steroids entirely, and has remained in remission with maintenance cetirizine and ranitidine ever since.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
